Skip to Main Content

Author Details

Bernd Wullich
University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)
1989
310
39
PMIDPaper TitleJournal TitlePublished Year
37031005Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.Eur Urol2024
37748510[Geriatric assessment - What should be done and considered before starting therapy of mHSPC and mCRPC?]Aktuelle Urol2024
37562993Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.Eur Urol Oncol2024
37031005Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.Eur Urol2024
37562993Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.Eur Urol Oncol2024
37748510[Geriatric assessment - What should be done and considered before starting therapy of mHSPC and mCRPC?]Aktuelle Urol2024
34583948Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort.J Clin Pathol2023
36372626Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.Eur Urol2023
37931610Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE Study.Urol Int2023
37813744Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].Eur Urol Oncol2023
37868689<i>PD-L1</i> (<i>CD274</i>) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.Oncoimmunology2023
37348477Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.Urol Int2023
37348477Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.Urol Int2023
36748180Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.BJU Int2023
36542416Retrospective histological evaluation of orchiectomy specimens following testicular torsion reveals a 10% incidence of reversible injury. Is it time for a change of strategy?Andrology2023
36534531Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.Clin Cancer Res2023
37524573Preoperative hormone stimulation; does it increase hypospadias postoperative complications?J Pediatr Urol2023
34583948Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort.J Clin Pathol2023
37524573Preoperative hormone stimulation; does it increase hypospadias postoperative complications?J Pediatr Urol2023
37931610Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE Study.Urol Int2023
37813744Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].Eur Urol Oncol2023
37868689<i>PD-L1</i> (<i>CD274</i>) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.Oncoimmunology2023
37348477Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.Urol Int2023
37348477Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.Urol Int2023
36748180Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.BJU Int2023
36542416Retrospective histological evaluation of orchiectomy specimens following testicular torsion reveals a 10% incidence of reversible injury. Is it time for a change of strategy?Andrology2023
36534531Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.Clin Cancer Res2023
36372626Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.Eur Urol2023
34330652High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer.Urol Oncol2022
35654002The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.Urol Int2022
35654002The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.Urol Int2022
35956173New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial.J Clin Med2022
35949808Immunohistochemical analysis of sex hormone receptors in squamous changes of the urothelium.Int J Clin Exp Pathol2022
35629399Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients.Life (Basel)2022
35629309Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors.Life (Basel)2022
35874589Urethral Plate Characteristics in Cases of Non-proximal Hypospadias May Not Be Associated With a Higher Risk of Complications When a Two-Stage Repair Is Applied.Front Pediatr2022
35366569C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.Eur J Cancer2022
36136143Expression of nectin-4 in papillary renal cell carcinoma.Discov Oncol2022
36136143Expression of nectin-4 in papillary renal cell carcinoma.Discov Oncol2022
36195073The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey.Urol Int2022
35925243[Biobanks, translational research and medical informatics].Urologie2022
36429046Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients.Cells2022
35399715Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.J Cancer2022
35399715Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.J Cancer2022
34330652High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer.Urol Oncol2022
34906411Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.Urol Oncol2022
34781290Transplant Ureteral Stenosis after Renal Transplantation: Risk Factor Analysis.Urol Int2022
35180650The prognostic impact of Claudin 6 in papillary renal cell carcinoma.Pathol Res Pract2022
35180650The prognostic impact of Claudin 6 in papillary renal cell carcinoma.Pathol Res Pract2022
35148991The renal cancer risk allele at 14q24.2 activates a novel hypoxia-inducible transcription factor-binding enhancer of DPF3 expression.J Biol Chem2022
  • 1 - 50 of 620

Recommended Authors

Brian D Robinson
Sandra and Edward Meyer Cancer Center
Career Start Year 2008
Number of shared co-authors 3
Fadi Brimo
McGill University Health Centre, McGill University
Career Start Year 2007
Number of shared co-authors 6
Roula Albadine
Centre hospitalier de l'Universite de Montreal
Career Start Year 2006
Number of shared co-authors 1
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 6
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 3
Mathieu Latour
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2001
Number of shared co-authors 3
Feliksas Jankevicius
Clinic of Gastroenterology, Vilnius University
Career Start Year 1995
Number of shared co-authors 0
David Clouston
Career Start Year 1995
Number of shared co-authors 4
Louis Lacombe
CHU de Quebec-Universite Laval
Career Start Year 1994
Number of shared co-authors 5
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 0
Bhaskar Kallakury
Georgetown University
Career Start Year 1993
Number of shared co-authors 0
Penny Flohr
The Institute of Cancer Research
Career Start Year 1993
Number of shared co-authors 0
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 6
Nicolas Mottet
Hospitalier Universitaire de Saint-Etienne
Career Start Year 1989
Number of shared co-authors 3
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 1
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 1
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 3
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 7
Victor E Reuter
Memorial Sloan Kettering Cancer Center
Career Start Year 1983
Number of shared co-authors 7
Joseph L Chin
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 2
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 1
David E Neal
University of Oxford, John Radcliffe Hospital
Career Start Year 1981
Number of shared co-authors 4
Hendrik Van Poppel
University Hospitals Leuven
Career Start Year 1981
Number of shared co-authors 5
Lawrence D True
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 3
Bernard T??tu
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Career Start Year 1979
Number of shared co-authors 3
Maria J Merino
National Cancer Institute, National Institutes of Health
Career Start Year 1977
Number of shared co-authors 5
Daniel M Berney
Barts Cancer Institute, Queen Mary University of London
Career Start Year 1975
Number of shared co-authors 5
Yves Fradet
CHU de Quebec-Universite Laval
Career Start Year 1975
Number of shared co-authors 7
Bogdan Czerniak
University of Texas MD Anderson Cancer Center
Career Start Year 1975
Number of shared co-authors 4
Hartwig Huland
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Career Start Year 1971
Number of shared co-authors 4

Collaborators

Abbas Agaimy
Institute of Pathology, Friedrich-Alexander University Erlangen-Nurnberg (FAU)
Co-authored papers 16
J??rn Kamradt
Clinic of Urology and Pediatric Urology, University of Saarland
Co-authored papers 13
Volker Jung
Clinic of Urology and Pediatric Urology, University of Saarland
Co-authored papers 11
Michael Stoeckle
Saarland University
Co-authored papers 8
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 6
Kai-Uwe Eckardt
Co-authored papers 6
Arnulf Stenzl
Eberhard Karls University of Tubingen
Co-authored papers 4
J??rg Rahnenf??hrer
TU Dortmund University
Co-authored papers 4
Thomas Ganslandt
Friedrich-Alexander-Universitat Erlangen-Nurnberg
Co-authored papers 4
Guido Sauter
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 3
Alexandre R Zlotta
University Health Network, Princess Margaret Cancer Center, University of Toronto
Co-authored papers 3
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Co-authored papers 3
Michiel S van der Heijden
the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Co-authored papers 3
Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
Co-authored papers 2
Norbert Graf
Clinical Trials Unit
Co-authored papers 2
Michael Gombert
Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf
Co-authored papers 2
Francisco X Real
Spanish National Cancer Research Centre-CNIO
Co-authored papers 1
Manuela Krumbholz
University Hospital Erlangen
Co-authored papers 1
Sabine M Klauck
Co-authored papers 1
Almut Nebel
Co-authored papers 1
Stefan Schreiber
Co-authored papers 1
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 1
Markus Metzler
University Hospital Erlangen
Co-authored papers 1
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Andreas von Deimling
Co-authored papers 1
Martin K Schilling
University Hospital of Homburg/Saar (DE)
Co-authored papers 1
Philip Rosenstiel
Co-authored papers 1
Lars Egevad
Karolinska Institute
Co-authored papers 1
Susan R Davis
Co-authored papers 1
Sean Davis
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 1
Release 1.2